Skip to main content
. 2022 Jan 18;66(1):e01263-21. doi: 10.1128/AAC.01263-21

FIG 3.

FIG 3

Adult and adolescent study design. Note that participants were randomly assigned in a 13:3 (part 1) or 14:3 (part 2) ratio to active:placebo for the duration of all study periods. The dosing interval for part 2 period 2 was determined after the interim data review of part 1 adult data.